Zobrazeno 1 - 1
of 1
pro vyhledávání: '"35"'
Publikováno v:
Journal of Clinical Oncology. 37:e12533-e12533
e12533 Background: Abemaciclib is a selective inhibitor of CDK4 and CDK6 kinase activity. It is approved for patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, advanced or metastatic breast cancer